As of April 17, 2026, Immunome's top three insider holders are Isaac Barchas (Director, 4.07Mn shares), Michael Rapp (Director, 1.07Mn shares), Clay B Siegall (President And Ceo, 690.70K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Isaac Barchas | - | 0 | 4,073,613 | 23 Dec, 2025 |
| Michael Rapp | - | 1,071,172 | 0 | 03 Oct, 2023 |
| Clay B Siegall | President And Ceo | 690,704 | 0 | 31 Mar, 2026 |
| Philip Wagenheim | - | 341,147 | 0 | 23 Mar, 2026 |
| Michael Rapp | - | 0 | 208,742 | 14 Sep, 2021 |
| John L Lamattina | - | 66,953 | 0 | 17 Jan, 2023 |
| Franklyn G Prendergast | - | 60,840 | 0 | 02 Oct, 2023 |
| Max Rosett | Chief Financial Officer | 54,037 | 0 | 03 Apr, 2026 |
| Philip Tsai | Chief Technical Officer | 43,300 | 0 | 22 Dec, 2025 |
| Bruce Turner | Chief Strategy Officer | 42,300 | 0 | 02 Oct, 2023 |
| Michael Lefenfeld | - | 40,747 | 0 | 17 Jan, 2023 |
| Jean Jacques Bienaime | - | 38,415 | 0 | 12 Mar, 2026 |
| Jack Higgins | Chief Scientific Officer | 22,000 | 0 | 03 Apr, 2026 |
| Robert Lechleider | Chief Medical Officer | 15,805 | 0 | 21 Nov, 2024 |
| Jack Higgins | Chief Scientific Officer | 0 | 3,000 | 22 Dec, 2025 |
| Richard A Baron | - | 2,343 | 0 | 20 Aug, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Apr, 2026 | Jack Higgins | Common Stock | D | 9,438 | $21.64 | 22,000 | D | S |
| 02 Apr, 2026 | Max Rosett | Common Stock | A | 31,848 | $1.05 | 79,324 | D | M |
| 02 Apr, 2026 | Max Rosett | Common Stock | A | 39,713 | $1.35 | 119,037 | D | M |
| 02 Apr, 2026 | Max Rosett | Common Stock | D | 63,656 | $21.91 | 55,381 | D | S |
| 02 Apr, 2026 | Max Rosett | Common Stock | D | 1,344 | $22.48 | 54,037 | D | S |
| 02 Apr, 2026 | Max Rosett | Stock option (right to buy) | D | 31,848 | $0.00 | 60,000 | D | M |
| 02 Apr, 2026 | Max Rosett | Stock option (right to buy) | D | 39,713 | $0.00 | 0 | D | M |
| 30 Mar, 2026 | Jack Higgins | Common Stock | D | 6,291 | $0.00 | 31,438 | D | G |
| 27 Mar, 2026 | Clay B Siegall | Common Stock | A | 25,450 | $19.67 | 690,704 | D | P |
| 20 Mar, 2026 | Philip Wagenheim | Common Stock | D | 36,800 | $20.47 | 369,347 | D | S |
| 23 Mar, 2026 | Philip Wagenheim | Common Stock | D | 28,200 | $20.65 | 341,147 | D | S |
| 10 Mar, 2026 | Jean Jacques Bienaime | Common Stock | A | 1,000 | $22.12 | 37,415 | D | P |
| 11 Mar, 2026 | Jean Jacques Bienaime | Common Stock | A | 1,000 | $21.55 | 38,415 | D | P |
| 30 Dec, 2025 | Clay B Siegall | Common Stock | A | 4,729 | $21.15 | 665,254 | D | P |
| 22 Dec, 2025 | Isaac Barchas | Common Stock | D | 371,949 | $21.72 | 2,042,432 | I | S |
| 22 Dec, 2025 | Isaac Barchas | Common Stock | D | 11,251 | $22.34 | 2,031,181 | I | S |
| 19 Dec, 2025 | Clay B Siegall | Common Stock | A | 7,278 | $20.48 | 860,525 | D | P |
| 19 Dec, 2025 | Philip Tsai | Common Stock | A | 10,000 | $20.49 | 43,300 | D | P |
| 19 Dec, 2025 | Jack Higgins | Common Stock | D | 1,000 | $0.00 | 39,729 | D | G |
| 19 Dec, 2025 | Jack Higgins | Common Stock | A | 1,000 | $0.00 | 1,000 | I | G |